Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 7%
Sell 7%
Strong Sell 0%

Bulls say

Alkermes is in a strong position to capitalize on the growing market for treatments for psychiatric diseases, particularly with their new drug ALKS 2680. The company's success in the market will depend on its ability to effectively market and sell alixorexton to a wider range of physicians. However, the potential for significant revenue from this drug, combined with other potential applications for alixorexton, give Alkermes a positive outlook for future growth and success. With a strong focus on research and development and a solid financial position, Alkermes is well-positioned to continue developing and commercializing innovative treatments for unmet medical needs in the biopharmaceutical industry.

Bears say

Alkermes is dependent on third-party providers for crucial active drug products, and has a limited track record of successful commercialization of new products. While Alkermes's lead clinical candidate ALKS 2680 may be first to market in treating NT2, its efficacy is not as strong as in treating NT1, making it less competitive in the market. Additionally, there is limited evidence supporting the use of orexin in treating ADHD, posing a risk for Alkermes's ALKS 2680 in this indication.

Alkermes (ALKS) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 14 analysts, Alkermes (ALKS) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.